Approximately one-quarter of patients with active epilepsy are females of childbearing age, necessitating treatment with medications that are known teratogens during this vulnerable life stage. However, most women with epilepsy require chronic treatment with an antiepileptic drug (AED) to maintain seizure control. Pregnancy registries over the last 2 decades have provided incremental advances in our knowledge quantifying the teratogenic risks, but the most useful information to the prescribing clinician is findings that delineate differential risks amongst the AEDs.
展开▼
